Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey


Creative Commons License

TÜREL Ö. , Kisa A., McIntosh E. D. G. , Bakir M.

VALUE IN HEALTH, vol.16, no.5, pp.755-759, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 5
  • Publication Date: 2013
  • Doi Number: 10.1016/j.jval.2013.03.1632
  • Title of Journal : VALUE IN HEALTH
  • Page Numbers: pp.755-759

Abstract

Background: Pneumococcal infection is an important and preventable cause of morbidity and mortality. The Turkish government introduced 7-valent pneumococcal conjugate vaccine (PCV) into the national immunization program in 2009. This suggests that replacing 7-valent PCV with a higher-valent version could at least maintain "standard of care" if not improve it, and that it could be affordable. Objectives and Methods: The aim of this analysis was to assess the potential direct cost-effectiveness of 13-valent PCV in Turkey, a country with a birth cohort of 1.4 million, against a "no vaccine" state, against the default 7-valent PCV state, and against a 10-valent PCV state, using a published cohort model with a 5-year horizon. Results and Conclusions: The cost per life-year gained is below the 1 x per-capita gross domestic product threshold across large changes in key input parameters, indicating that the model is stable and suggesting that any PCV would be very cost-effective in a Turkish national pediatric immunization schedule.